TITLE

Green Light from the FDA for New Drug Development in Irritable Bowel Syndrome and Functional Dyspepsia

AUTHOR(S)
Talley, Nicholas J.
PUB. DATE
June 2009
SOURCE
American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1339
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on the U.S. Food & Drug Administration (FDA) supporting the development of new medicine to counter irritable bowel syndrome (IBS) and functional dyspepsia (FD). It is said that at least 10% of Americans are afflicted with IBS. After the pharmaceutical industry adopted a global end-point methodology for judging efficacy, new drug trials greatly accelerated with FDA accepting the end point.
ACCESSION #
40737228

 

Related Articles

  • Novartis' Zelnorm 'not approvable'  // Medical Marketing & Media;Aug2001, Vol. 36 Issue 8, p29 

    Reports on the issuance of a 'not approval' letter by the U.S. Food and Drug Administration to Novartis for Zelnorm, a drug developed by Novartis for irritable bowel treatment. Request for additional data on gall bladder surgery; Petition from the Public Citizen organization; Response of Novartis.

  • Guidance for Industry on Irritable Bowel Syndrome--Clinical Evaluation of Drugs for Treatment; Availability. Kux, Leslie // Federal Register (National Archives & Records Service, Office of;5/31/2012, Vol. 77 Issue 105, p32124 

    The article presents information on a notice issued by the U.S. Food and Drug Administration regarding availability of a guidance titled "''Irritable Bowel Syndrome- Clinical Evaluation of Drugs for Treatment." This guidance will assist the pharmaceutical industry and the investigators who are...

  • Med Safety actions in brief.  // Formulary;Sep2007, Vol. 42 Issue 9, p525 

    The article reports on the permission of restricted use of tegaserod with brand name Zelnorm from Novartis AG by the U.S. Food and Drug Administration. It is under a treatment investigational new drug protocol for the treatment of irritable bowel syndrome with constipation and chronic idiopathic...

  • PIPELINE PREVIEW.  // Formulary;Jul2001, Vol. 36 Issue 7, p481 

    Provides updates on drugs designation by the United States Food and Drug Administration as of July 2001. Recommendations for approval of B-type natriuretic peptide nesiritide; Nonapproval of tegaserod maleate for bowel syndrome treatment; Designations of purified poloxamer 188 for treatment of...

  • Defining the Similarity of Dissolution Profiles Using Hotelling's T[sup2] Statistic. Saranadasa, Hewa // Pharmaceutical Technology Asia;Apr2002, p26 

    Describes a method for assessing the similarity of dissolution profiles through Hotelling's T² statistic. Comparison of the method to the f[sub2] criterion recommended by the U.S. Food and Drug Administration's guidance on dissolution testing; Results of applications of the methods;...

  • FDA Champions Risk-Based Analysis for 21 CFR Part 11. Keating, Sean // Drug Discovery & Development;Jun2003, Vol. 6 Issue 6, p59 

    Focuses on the United States Food and Drug Administration's (FDA) 21 CFR Part 11 regulation issued March 1997 which provides guidelines on drug development for pharmaceutical companies. Problems associated with pharmaceutical industry's compliance to guidelines; Provisions; Compliance problems...

  • A year of opportunities. Tosh, Mark // Medical Marketing & Media;Jan2003, Vol. 38 Issue 1, p3 

    Presents an overview of articles found in the January 2003 issue of the journal 'Medical Marketing & Media.' Prediction on the backlog of the New Drug Application of the U.S. Food and Drug Administration; List of late-stage development drug products; Techniques in repairing damage caused by...

  • Big Spenders Still Seek Approvals.  // Pharmaceutical Executive;Mar2005, Vol. 25 Issue 3, p34 

    Focuses on the efforts of Big Pharma in seeking approvals for new molecular entities (NME) from the U.S. Food and Drugs Administration (FDA) in 2004. Number of NME approved by the FDA in 2004; Amount spent by Big Pharma in its drug research and development projects; Condition of the research and...

  • Better Future for Pharma/Biotech? Agres, Ted // Drug Discovery & Development;Dec2002, Vol. 5 Issue 11, p15 

    Discusses the prospects of pharmaceutical companies in the United States for 2003. Problems encountered by the industry during 2002; Pending approvals for biotech medicines from the U.S. Food and Drug Administration (FDA); Average cost to bring a new drug to the market; Factors influencing the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics